Rosacea Treatments: What's new and what's on the Horizon?

American Journal of Clinical Dermatology

Volumn 11, Issue 5, 2010, Pages 299-303

  Gallo, Rosella ^a   Drago, Francesco ^a   Paolino, Stefania ^a   Parodi, Aurora ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; AZELAIC ACID; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; COLECALCIFEROL; CROTAMITON; DOXYCYCLINE; METRONIDAZOLE; OXYMETAZOLINE; PERMETHRIN; RETINOID; RIFAXIMIN; TETRACYCLINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN;

ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; BACILLUS OLERONIUS INFESTATION; BACTERIAL SKIN DISEASE; BLEPHARITIS; BLOOD VESSEL DYSREGULATION; DEMODICOSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DRUG INHIBITION; DRUG MECHANISM; DYSPEPSIA; HELICOBACTER INFECTION; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; ROSACEA; SKIN BIOPSY; SKIN INFLAMMATION; SMALL INTESTINE BACTERIAL OVERGROWTH; SMALL INTESTINE DISEASE; VASCULAR DISEASE; BACILLUS; BLIND LOOP SYNDROME; COMPLICATION; GASTROINTESTINAL TRACT; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; METABOLISM; MICROBIOLOGY; MITE INFESTATIONS; PHOTOTHERAPY; SKIN;

ADRENERGIC ALPHA-AGONISTS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACILLUS; BLIND LOOP SYNDROME; CHOLECALCIFEROL; GASTROINTESTINAL TRACT; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MITE INFESTATIONS; PERMETHRIN; PHOTOTHERAPY; ROSACEA; SKIN;

EID: 77954809925     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11537020-000000000-00000     Document Type: Review

References (37)

1. Powell FC. Rosacea. N Engl J Med 2005; 352: 793-803
2. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2002; 46: 584-587
3. Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2004; 50: 907-912
4. van Zuuren EJ, Gupta AK, Gover MD, et al. Systematic review of rosacea treatments. J Am Acad Dermatol 2007; 56: 107-115
5. Marks R, Beard RJ, Clark ML, et al. Gastrointestinal observations in rosacea. Lancet 1967; 1: 739-743
6. Zhang H, Liao W, Chao W, et al. Risk factors for sebaceous gland diseases and their relationship to gastrointestinal dysfunction in Han adolescents. J Dermatol 2008; 35: 555-561
7. Rebora A, Drago F, Parodi A. May Helicobacter pylori be important for dermatologists? Dermatology 1995; 191: 6-8
8. Szlachcic A, Sliwowski Z, Karczewska E, et al. Helicobacter pylori and its eradication in rosacea. J Physiol Pharmacol 1999; 50: 777-786
9. Saccà SC, Pascotto A, Venturino GM, et al. Prevalence and treatment of Helicobacter pylori in patients with blepharitis. InvestOphthalmol Vis Sci 2006; 47: 501-508
10. Diaz C, O'Callaghan CJ, Khan A, et al. Rosacea: a cutaneous marker of Helicobacter pylori infection?Results of a pilot study. Acta Derm Venereol 2003; 83: 282-286
11. Diamantis S, Waldorf HA. Rosacea: clinical presentation and pathophysiology. J Drugs Dermatol 2006; 5: 8-12
12. Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol 2008; 6: 759-764
13. Rebora A. The management of rosacea. Am J Clin Dermatol 2002; 3: 489-496
14. Lacey N, Delaney S, Kavanagh K, et al. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol 2007; 157: 476-481
15. Dahl MV, Ross AJ., Schlievert PM. Temperature regulates bacterial protein production: possible role in rosacea. J Am Acad Dermatol 2004; 50: 266-272.
16. Bonnar E, Eustace P, Powell FC. The Demodex mite population in rosacea. J Am Acad Dermatol 1993; 28: 443-448.
17. Forton F, Seys B. Density of Demodex folliculorum in rosacea: a case control study using standardized skin surface biopsy. Br J Dermatol 1993; 128: 650-659.
18. Schauber J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol 2008; 122: 261-266.
19. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007; 13: 975-980
20. Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25- dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004; 173: 2909-2912.
21. Jansen T, Krug S, Kind P, et al. BsmI polymorphism of the vitamin D receptor gene in patients with the fulminant course of rosacea conglobata (rosacea fulminans). J Dermatol 2004; 31: 244-246.
22. Segaert S. VitaminDregulation of cathelicidin in the skin: toward a renaissance of vitamin D in dermatology? J Invest Dermatol 2008; 128: 773-775.
23. Berman B, Perez OA, Zell D. Update on rosacea and anti-inflammatory dose doxycycline. Drugs Today 2007; 43: 27-34.
24. Del Rosso J. Recently approved systemic therapies for acne vulgaris and rosacea. Cutis 2007; 80: 113-120
25. AlikhanA, Kurek L, Feldman S, et al. The role of tetracyclines in rosacea.AmJ Clin Dermatol 2010; 11 (2): 79-87.
26. McKeage K, Deeks ED. Doxycycline 40mg capsules (30mg immediaterelease/ 10 mg delayed-release beads): anti-inflammatory dose in rosacea. Am J Clin Dermatol 2010; 11 (3): 217-222.
27. Golinick H, Layton A. Azelaic acid 15%gel in the treatment of rosacea. Expert Opin Pharmacother 2008; 9: 2699-2706.
28. US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/results?term=rosacea [Accessed 2010 Jun 11].
29. Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol 2007; 143: 1369-1371.
30. Franchimont CP, Quatresooz P, Pierard GE. Incidental control of rosacea by somatostatin. Dermatology 2003; 206: 249-251.
31. Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220: 524-527.
32. Mark KA, Sparacio RM, Voigt A, et al. Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment. Dermatol Surg 2003; 29: 600-604.
33. Taub A. Treatment of rosacea with intense pulsed light. J Drugs Dermatol 2003; 2: 254-259.
34. Papageorgiou P, Clayton W, Norwood S, et al. Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol 2008; 159: 628-632.
35. Bikowsli JB, Del Rosso JQ, Goldberg DJ, et al. Future trends in the treatment of rosacea. Cutis 2005; 75: 33-36.
36. Bryld LE, Jemec GBE. Photodynamic therapy in a series of rosacea patients. JEADV 2007; 21: 1199-1202.
37. Katz B, Patel V. Photodynamic therapy for the treatment of erythema, papules, pustules and severe flushing consistent with rosacea. J Drugs Dermatol 2006; 5: 6-8.